1
|
Forbes JM and Cooper ME: Mechanisms of
diabetic complications. Physiol Rev. 93:137–188. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Guariguata L, Whiting DR, Hambleton I,
Beagley J, Linnenkamp U and Shaw JE: Global estimates of diabetes
prevalence for 2013 and projections for 2035. Diabetes Res Clin
Pract. 103:137–149. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Collins AJ, Foley RN, Chavers B,
Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J,
Peter W St, et al: United States Renal Data System 2011 Annual Data
Report: Atlas of chronic kidney disease & end-stage renal
disease in the United States. Am J Kidney Dis. 59(Suppl 1):
A7e1–420. 2012. View Article : Google Scholar
|
4
|
Eid AA, Ford BM, Block K, Kasinath BS,
Gorin Y, Ghosh-Choudhury G, Barnes JL and Abboud HE: AMP-activated
protein kinase (AMPK) negatively regulates Nox4-dependent
activation of p53 and epithelial cell apoptosis in diabetes. J Biol
Chem. 285:37503–37512. 2010. View Article : Google Scholar : PubMed/NCBI
|
5
|
Eid AA, Gorin Y, Fagg BM, Maalouf R,
Barnes JL, Block K and Abboud HE: Mechanisms of podocyte injury in
diabetes: Role of cytochrome P450 and NADPH oxidases. Diabetes.
58:1201–1211. 2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Kim DK, Nam BY, Li JJ, Park JT, Lee SH,
Kim DH, Kim JY, Kang HY, Han SH, Yoo TH, et al: Translationally
controlled tumour protein is associated with podocyte hypertrophy
in a mouse model of type 1 diabetes. Diabetologia. 55:1205–1217.
2012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Susztak K, Raff AC, Schiffer M and
Bottinger EP: Glucose-induced reactive oxygen species cause
apoptosis of podocytes and podocyte depletion at the onset of
diabetic nephropathy. Diabetes. 55:225–233. 2006. View Article : Google Scholar
|
8
|
Weil EJ, Lemley KV, Mason CC, Yee B, Jones
LI, Blouch K, Lovato T, Richardson M, Myers BD and Nelson RG:
Podocyte detachment and reduced glomerular capillary endothelial
fenestration promote kidney disease in type 2 diabetic nephropathy.
Kidney Int. 82:1010–1017. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Faul C, Asanuma K, Yanagida-Asanuma E, Kim
K and Mundel P: Actin up: Regulation of podocyte structure and
function by components of the actin cytoskeleton. Trends Cell Biol.
17:428–437. 2007. View Article : Google Scholar : PubMed/NCBI
|
10
|
Li Y, Kang YS, Dai C, Kiss LP, Wen X and
Liu Y: Epithelial-to-mesenchymal transition is a potential pathway
leading to podocyte dysfunction and proteinuria. Am J Pathol.
172:299–308. 2008. View Article : Google Scholar : PubMed/NCBI
|
11
|
Pavenstädt H, Kriz W and Kretzler M: Cell
biology of the glomerular podocyte. Physiol Rev. 83:253–307. 2003.
View Article : Google Scholar
|
12
|
Durvasula RV and Shankland SJ: Podocyte
injury and targeting therapy: An update. Curr Opin Nephrol
Hypertens. 15:1–7. 2006. View Article : Google Scholar
|
13
|
Kang YS, Li Y, Dai C, Kiss LP, Wu C and
Liu Y: Inhibition of integrin-linked kinase blocks podocyte
epithelial-mesenchymal transition and ameliorates proteinuria.
Kidney Int. 78:363–373. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Yamaguchi Y, Iwano M, Suzuki D, Nakatani
K, Kimura K, Harada K, Kubo A, Akai Y, Toyoda M, Kanauchi M, et al:
Epithelial-mesenchymal transition as a potential explanation for
podocyte depletion in diabetic nephropathy. Am J Kidney Dis.
54:653–664. 2009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Dai H, Liu Q and Liu B: Research progress
on mechanism of podocyte depletion in diabetic nephropathy. J
Diabetes Res. 2017:1–10. 2017. View Article : Google Scholar
|
16
|
Boon RA, Jaé N, Holdt L and Dimmeler S:
Long Noncoding RNAs: From clinical genetics to therapeutic targets.
J Am Coll Cardiol. 67:1214–1226. 2016. View Article : Google Scholar : PubMed/NCBI
|
17
|
Qiu MT, Hu JW, Yin R and Xu L: Long
noncoding RNA: An emerging paradigm of cancer research. Tumour
Biol. 34:613–620. 2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Gibb EA, Warren RL, Wilson GW, Brown SD,
Robertson GA, Morin GB and Holt RA: Activation of an endogenous
retrovirus-associated long non-coding RNA in human adenocarcinoma.
Genome Med. 7:222015. View Article : Google Scholar : PubMed/NCBI
|
19
|
Zhang H, Chen Z, Wang X, Huang Z, He Z and
Chen Y: Long non-coding RNA: A new player in cancer. J Hematol
Oncol. 6:372013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Amit-Avraham I, Pozner G, Eshar S, Fastman
Y, Kolevzon N, Yavin E and Dzikowski R: Antisense long noncoding
RNAs regulate var gene activation in the malaria parasit Plasmodium
falciparum. Proc Natl Acad Sci USA. 112:E982–E991. 2015. View Article : Google Scholar
|
21
|
Hung CL, Wang LY, Yu YL, Chen HW,
Srivastava S, Petrovics G and Kung HJ: A long noncoding RNA
connects c-Myc to tumor metabolism. Proc Natl Acad Sci USA.
111:18697–18702. 2014. View Article : Google Scholar : PubMed/NCBI
|
22
|
Alvarez ML and Distefano JK: The role of
non-coding RNAs in diabetic nephropathy: Potential applications as
biomarkers for disease development and progression. Diabetes Res
Clin Pract. 99:1–11. 2013. View Article : Google Scholar
|
23
|
Ding GL, Wang FF, Shu J, Tian S, Jiang Y,
Zhang D, Wang N, Luo Q, Zhang Y, Jin F, et al: Transgenerational
glucose intolerance with Igf2/H19 epigenetic alterations in mouse
islet induced by intrauterine hyperglycemia. Diabetes.
61:1133–1142. 2012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Yan B, Tao ZF, Li XM, Zhang H, Yao J and
Jiang Q: Aberrant expression of long noncoding RNAs in early
diabetic retinopathy. Invest Ophthalmol Vis Sci. 55:941–951. 2014.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Wang M, Wang S, Yao D, Yan Q and Lu W: A
novel long non-coding RNA CYP4B1-PS1-001 regulates proliferation
and fibrosis in diabetic nephropathy. Mol Cell Endocrinol.
426:136–145. 2016. View Article : Google Scholar : PubMed/NCBI
|
26
|
Wang WT, Ye H, Wei PP, Han BW, He B, Chen
ZH and Chen YQ: LncRNAs H19 and HULC, activated by oxidative
stress, promote cell migration and invasion in cholangiocarcinoma
through a ceRNA manner. J Hematol Oncol. 9:1172016. View Article : Google Scholar : PubMed/NCBI
|
27
|
Chen T, Zheng LY, Xiao W, Gui D, Wang X
and Wang N: Emodin ameliorates high glucose induced-podocyte
epithelia-mesenchymal transition in-vitro and in-vivo. Cell Physiol
Biochem. 35:1425–1436. 2015. View Article : Google Scholar
|
28
|
Roy S, Rahaman N, Ahmed F, Metya S and
Sannigrahi S: Naringenin attenuates testicular damage, germ cell
death and oxidative stress in streptozotocin induced diabetic rats:
naringenin prevents diabetic rat testicular damage. J Applied
Biomedicine. 11:195–208. 2013. View Article : Google Scholar
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔC T method. Methods. 25:402–408.
2001. View Article : Google Scholar
|
30
|
Xu X, Luo P, Wang Y, Cui Y and Miao L:
Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) is a novel
therapeutic target for diabetic complications. J Int Med Res.
41:13–19. 2013. View Article : Google Scholar : PubMed/NCBI
|
31
|
Mundel P and Shankland SJ: Podocyte
biology and response to injury. J Am Soc Nephrol. 13:3005–3015.
2002. View Article : Google Scholar : PubMed/NCBI
|
32
|
Wiggins RC: The spectrum of
podocytopathies: A unifying view of glomerular diseases. Kidney
Int. 71:1205–1214. 2007. View Article : Google Scholar : PubMed/NCBI
|
33
|
Yu D, Petermann A, Kunter U, Rong S,
Shankland SJ and Floege J: Urinary podocyte loss is a more specific
marker of ongoing glomerular damage than proteinuria. J Am Soc
Nephrol. 16:1733–1741. 2005. View Article : Google Scholar : PubMed/NCBI
|
34
|
Cooper ME, Mundel P and Boner G: Role of
nephrin in renal disease including diabetic nephropathy. Semin
Nephrol. 22:393–398. 2002. View Article : Google Scholar : PubMed/NCBI
|
35
|
Benigni A, Gagliardini E, Tomasoni S,
Abbate M, Ruggenenti P, Kalluri R and Remuzzi G: Selective
impairment of gene expression and assembly of nephrin in human
diabetic nephropathy. Kidney Int. 65:2193–2200. 2004. View Article : Google Scholar : PubMed/NCBI
|
36
|
Sassetti C, Tangemann K, Singer MS,
Kershaw DB and Rosen SD: Identification of podocalyxin-like protein
as a high endothelial venule ligand for L-selectin: Parallels to
CD34. J Exp Med. 187:1965–1975. 1998. View Article : Google Scholar : PubMed/NCBI
|
37
|
Hara M, Yamagata K, Tomino Y, Saito A,
Hirayama Y, Ogasawara S, Kurosawa H, Sekine S and Yan K: Urinary
podocalyxin is an early marker for podocyte injury in patients with
diabetes: Establishment of a highly sensitive ELISA to detect
urinary podocalyxin. Diabetologia. 55:2913–2919. 2012. View Article : Google Scholar : PubMed/NCBI
|
38
|
Xing Y, Ye S and Chen Y, Hu W and Chen Y:
Hydrochloride pioglitazone protects diabetic rats against podocyte
injury through preserving glomerular podocalyxin expression. Arq
Bras Endocrinol Metabol. 58:630–639. 2014. View Article : Google Scholar : PubMed/NCBI
|
39
|
Ataei N, Bazargani B, Ameli S, Madani A,
Javadilarijani F, Moghtaderi M, Abbasi A, Shams S and Ataei F:
Early detection of acute kidney injury by serum cystatin C in
critically ill children. Pediatr Nephrol. 29:133–138. 2014.
View Article : Google Scholar
|
40
|
Sharifiaghdas F, Kashi AH and Eshratkhah
R: Evaluating percutaneous nephrolithotomy-induced kidney damage by
measuring urinary concentrations of beta2-microglobulin. Urol J.
8:277–282. 2011.PubMed/NCBI
|
41
|
Shimizu A, Horikoshi S, Rinnno H, Kobata
M, Saito K and Tomino Y: Serum cystatin C may predict the early
prognostic stages of patients with type 2 diabetic nephropathy. J
Clin Lab Anal. 17:164–167. 2003. View Article : Google Scholar : PubMed/NCBI
|
42
|
Zhou L, Xu DY, Sha WG, Shen L, Lu GY and
Yin X: Long non-coding MIAT mediates high glucose-induced renal
tubular epithelial injury. Biochem Biophys Res Commun. 468:726–732.
2015. View Article : Google Scholar : PubMed/NCBI
|
43
|
Beltrami C, Angelini TG and Emanueli C:
Noncoding RNAs in diabetes vascular complications. J Mol Cell
Cardiol. 89:42–50. 2015. View Article : Google Scholar
|
44
|
Hu M, Wang R, Li X, Fan M, Lin J, Zhen J,
Chen L and Lv Z: LncRNA MALAT1 is dysregulated in diabetic
nephropathy and involved in high glucose-induced podocyte injury
via its interplay with β-catenin. J Cell Mol Med. 21:2732–2747.
2017. View Article : Google Scholar : PubMed/NCBI
|
45
|
Li D, Lu Z, Xu Z, Ji J, Zheng Z, Lin S and
Yan T: Spironolactone promotes autophagy via inhibiting
PI3K/AKT/mTOR signalling pathway and reduce adhesive capacity
damage in podocytes under mechanical stress. Biosci Rep. 36:pii:
362016. 2016. View Article : Google Scholar
|